Analyst Confidence and Insider Moves Shape Outlook for Gilead Sciences

As Gilead Sciences approaches a pivotal period, the investment community is weighing robust analyst upgrades against recent stock sales by the company's chief executive. This contrast presents a key question for shareholders: does the fundamental business strength outweigh the potential signal from these insider transactions?

The next significant test for the biopharmaceutical firm arrives on Tuesday, February 10, 2026. On that date, Gilead is scheduled to release its fourth-quarter and full-year 2025 financial results. Market participants will be closely watching to see if the company can once again surpass earnings-per-share expectations. Guidance concerning the future of its oncology portfolio will also be a major focus for investors.

The equity has demonstrated notable resilience recently. Currently trading at €119.70, the share price remains steady near its previous closing level. Over a 30-day period, the stock has advanced approximately 15%, showcasing outperformance relative to the broader healthcare sector.

Wall Street Revises Targets Upward

A wave of analyst optimism has swept through Wall Street in recent days. Multiple research firms have repositioned their outlooks on the biotechnology giant, issuing revised price targets and reaffirming bullish ratings.

Should investors sell immediately? Or is it worth buying Gilead Sciences?

A standout move came from Leerink Partners, which over the weekend raised its price objective from $114.00 to $146.00. This follows earlier upgrades from heavyweight institutions including Citigroup and UBS. These analysts increased their forecasts to as high as $156.00 while maintaining their buy recommendations.

This positive sentiment is largely driven by core business performance. Market observers point to strong momentum within the HIV segment, fueled in part by the launch of the prevention therapy Yeztugo. Furthermore, encouraging clinical data for the Trodelvy-Keytruda combination therapy in breast cancer is providing positive momentum for the company's oncology division.

Contextualizing the CEO's Stock Sales

Reports of share disposals by CEO Daniel O’Day have introduced a note of complexity to the narrative. In two separate transactions at the end of January, O’Day sold stock worth a combined total of around $17 million. However, the context of these sales is crucial.

The majority of these transactions were executed under a pre-arranged 10b5-1 trading plan, which was established back in February 2025. Such plans are designed to prevent accusations of insider trading by automating sales well in advance. Following these sales, O’Day retains a substantial stake in the company, holding over 560,000 shares. Consequently, these moves are widely interpreted as part of personal portfolio diversification rather than a vote of no confidence in the firm's prospects.